SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0001193125-19-019504
Filing Date
2019-01-29
Accepted
2019-01-28 21:34:45
Documents
7
Effectiveness Date
2019-01-29

Document Format Files

Seq Description Document Type Size
1 DEFR14A d678811ddefr14a.htm DEFR14A 1634736
2 GRAPHIC g678811apc1.jpg GRAPHIC 274984
3 GRAPHIC g678811apc2.jpg GRAPHIC 214945
4 GRAPHIC g678811bpc1.jpg GRAPHIC 173709
5 GRAPHIC g678811bpc2.jpg GRAPHIC 196955
6 GRAPHIC g678811g10g16.jpg GRAPHIC 29900
7 GRAPHIC g678811g30c53.jpg GRAPHIC 45469
  Complete submission text file 0001193125-19-019504.txt   2910348
Mailing Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511
Business Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511 312 767 0291
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-35405 | Film No.: 19547000
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences